GROM - GR

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Grom Social Enterprises a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Grom Social Enterprises..

Grom Social Enterprises (OTC:GROM) Azioni, Catena delle Opzioni

Grom Social Enterprises

Grom Social Enterprises Inc is a social media, technology, and entertainment company for kids focused on producing original content. In addition to providing a social media platform, the company creates content consisting of animated characters, interactive charts, videos, blogs, and games. It has three reportable business segments: Animation, which includes TDH; Original Content, which includes CIM; and Social & Technology, which includes GSOC and GEDU. The majority of its revenue is from the Animation segment.

GROM SOCIAL ENTERPRS INC by Grom Social Enterprises, Inc.

Grom Social Enterprises Inc

Grom Social Enterprises Inc Warrants (17/06/2026)

<p>Needham  analyst Ami Fadia   reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $28 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

ACAD

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target

<p><strong>Chicago Atlantic Admin </strong>acted as administrative agent on the funding<strong> of a $30 million senior secured credit facility for Deep Roots Holdings, </strong>a vertically integrated cannabis operator in Nevada. Deep Roots Holdings has a standalone cultivation and processing facility in the Silver State, runs five dispensaries and plans to open one more in Dec. 2024.</p>
<p>"Deep Roots is a company to watch in 2025, and it's our pleasure to take a front-row seat and support their growing investment portfolio," stated <strong>David Kite</strong>, managing partner at Chicago Atlantic. "Their team has shown operational expertise at every level, exceptional business acumen and a strong balance sheet – We couldn't be more excited to partner with them."</p>
<p>The capital provided by Chicago Atlantic, on behalf of its affiliated investment funds, will support Deep Roots Harvest's expansion as it takes on additional retail and cultivation assets across Nevada. In October 2024, Deep Roots Harvest <a href="https://www.benzinga.com/markets/cannabis/24/04/38450434/deep-roots-harvest-to-acquire-the-source-operation-in-nevada">acquired most of the asset</a>s of Nevada cannabis operator <strong>The Source Holdings, LLC,</strong> including four retail operations, two provisional retail licenses and one operating facility for cultivation.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41765421/south-dakota-rejects-measure-29-cannabis-legalization-fails-again">South Dakota Rejects Measure 29: Cannabis Legalization Fails Again</a></strong></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<p>The successful move positions Deep Roots to operate 12 total dispensaries and establishes them as the market share leader in Nevada.</p>
<p><strong>Keith Capurro</strong>, CEO of Deep Roots Harvest, said the company will continue its strategic growth in 2025 and beyond.</p>
<p>"Chicago Atlantic has quickly proven themselves as a valuable partner as we continue to invest across our portfolio of businesses," said Capurro. "With a larger balance sheet and meaningful additional borrowing capacity, we are well positioned to execute on our broader strategy."</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/23/07/33098371/chicago-firm-sees-value-in-ny-rec-market-speeds-up-roll-out-with-150m-investment">Chicago Firm Sees Value In NY Rec Market, Speeds Up Roll-Out With $150M Investment</a></strong></li>
</ul>
<p><em>Photo: Courtesy of Deep Roots Harvest via Business Wire </em></p>


Cannabis

Cannabis Operator Deep Roots Harvest Secures $30M From Chicago Atlantic To Expand Across Nevada

Health Care

General

ADPT

Adaptive Biotechnologies Announced That Palmetto GBA, A Medicare Administrative Contractor, Has Expanded Coverage Of clonoSEQ To Include Detection And Monitoring Of Measurable Residual Disease In Medicare Patients With Mantle Cell Lymphoma

<p>NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.0, a high estimate of $37.00, and a low estimate of $31.00. This current average reflects an increase of 0.95% from the previous average price target of $34.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984473_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NewAmsterdam Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of NewAmsterdam Pharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NewAmsterdam Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NAMS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on NewAmsterdam Pharma analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into NewAmsterdam Pharma's Background</h2>
<p>NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.</p>
<h3>Financial Milestones: NewAmsterdam Pharma's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> NewAmsterdam Pharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>32.73%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-1711.58%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> NewAmsterdam Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-9.76%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> NewAmsterdam Pharma's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.34%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> NewAmsterdam Pharma's debt-to-equity ratio is below the industry average. With a ratio of <b>0.0</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NAMS

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma

<p>Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high estimate of $70.00, and a low estimate of $55.00. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984463_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Ionis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ionis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Ionis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ionis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Ionis Pharmaceuticals</h2>
<p>Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.</p>
<h3>Key Indicators: Ionis Pharmaceuticals's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Ionis Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>19.55%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ionis Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-29.42%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Ionis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-23.66%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ionis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.43%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at <strong>5.47</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IONS

Where Ionis Pharmaceuticals Stands With Analysts

<p>5 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.4, a high estimate of $20.00, and a low estimate of $15.00. This current average has increased by 0.87% from the previous average price target of $17.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984454_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Amicus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dennis Ding</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Amicus Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Amicus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Amicus Therapeutics analyst ratings.</strong></a></p>
<h2>Discovering Amicus Therapeutics: A Closer Look</h2>
<p>Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.</p>
<h3>Financial Insights: Amicus Therapeutics</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Amicus Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>34.04%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Amicus Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-12.39%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Amicus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-11.93%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Amicus Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.13%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Amicus Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.35</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FOLD

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights

<p>During the last three months, 8 analysts shared their evaluations of Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $145.75, a high estimate of $160.00, and a low estimate of $126.00. Observing a 4.64% increase, the current average has risen from the previous average price target of $139.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984442_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Sun Communities by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$126.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$150.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$154.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$149.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$144.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$138.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Sun Communities's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sun Communities's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SUI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sun Communities analyst ratings.</strong></a></p>
<h2>All You Need to Know About Sun Communities</h2>
<p>Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.</p>
<h3>Key Indicators: Sun Communities's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Sun Communities displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>1.09%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Sun Communities's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>6.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sun Communities's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.75%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sun Communities's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.3%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.14</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 8 Ratings For Sun Communities

<p>Across the recent three months, 6 analysts have shared their insights on Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $92.0, a high estimate of $120.00, and a low estimate of $76.00. This current average has increased by 18.86% from the previous average price target of $77.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984429_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Q2 Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Michael Del Grosso</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Q2 Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Q2 Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Q2 Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Q2 Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QTWO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Q2 Holdings analyst ratings.</strong></a></p>
<h2>Discovering Q2 Holdings: A Closer Look</h2>
<p>Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.</p>
<h3>Q2 Holdings: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Q2 Holdings showcased positive performance, achieving a revenue growth rate of <strong>11.88%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Q2 Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-7.55%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Q2 Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.76%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Q2 Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.13</strong>, Q2 Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QTWO

Unveiling 6 Analyst Insights On Q2 Holdings

<p>Ratings for MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $259.75, a high estimate of $325.00, and a low estimate of $185.00. Witnessing a positive shift, the current average has risen by 8.0% from the previous average price target of $240.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730984418_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive MarketAxess Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$314.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$185.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$233.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$223.00</td>
<td>$218.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MarketAxess Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MarketAxess Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MarketAxess Holdings analyst ratings.</strong></a></p>
<h2>Delving into MarketAxess Holdings's Background</h2>
<p>Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Borse Group in 2020 adding to its product offerings.</p>
<h3>MarketAxess Holdings's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> MarketAxess Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.91%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> MarketAxess Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>32.85%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MarketAxess Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.91%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MarketAxess Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.41%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> MarketAxess Holdings's debt-to-equity ratio is below the industry average at <strong>0.06</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MKTX

Cracking The Code: Understanding Analyst Reviews For MarketAxess Holdings

<p>B of A Securities  analyst Ken Hoexter   upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Underperform to Buy and raises the price target from $27 to $34.</p>


Upgrades

SNDR

B of A Securities Upgrades Schneider National to Buy, Raises Price Target to $34

<p>Needham  analyst Mayank Tandon   maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Buy and raises the price target from $90 to $120.</p>


Needham Maintains Buy on Q2 Holdings, Raises Price Target to $120

<p>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) reported quarterly losses of $(1.24) per share which missed the analyst consensus estimate of $(1.08) by 14.81 percent. This is a 22.5 percent increase over losses of $(1.60) per share from the same period last year.</p>


Earnings

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Q3 2024 GAAP EPS $(1.24) Misses $(1.08) Estimate

<p>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.88) by 34.09 percent.</p>


Earnings Beats

SAVA

Cassava Sciences Q3 2024 GAAP EPS $(0.58) Beats $(0.88) Estimate

<p>Needham  analyst Bernie McTernan   reiterates Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and maintains $16 price target.</p>


SRAD

Needham Reiterates Buy on Sportradar Gr, Maintains $16 Price Target

<p>Burford Capital Limited, the leading global finance and asset management firm focused on law, has noted inaccurate media reporting and subsequent market reaction to an expected court filing last night by the U.S. Department of Justice ("DOJ") in the Petersen and Eton Park matters. The filing in the U.S. District Court for the Southern District of New York restates DOJ's position on a narrow question of law in relation to enforcement of judgments. The filing pertains to one motion filed in the Petersen and Eton Park matters as part of the overall, ongoing effort to enforce the judgment against the Argentine Republic. The filing does not reflect DOJ's taking any broader position on the overall case or the enforcement campaign; indeed, DOJ has previously taken the position that pursuing Argentina in the US courts for its breach of contract in this matter was appropriate, and DOJ has not made any filing at all on the pending appeal (and the time to do so has passed). In its filing, DOJ took the view that Argentina could not be required by a U.S. court to move property presently located in Argentina into the United States so it could there be attached for creditors under New York law, which is an unsettled legal issue. The DOJ view is not binding on the court and further briefing and proceedings will ensue. The Company will provide a further update on the Petersen and Eton Park matters during today's earnings call.</p>


Legal

Burford Capital Highlights Inaccurate Media Reports On DOJ Court Filing In Petersen, Eton Park Cases; Filing Focuses on Legal Enforcement Issue, Not Broader Case; DOJ States Argentina's Property Cannot Be Moved To U.S. For Creditor Attachment; The DOJ View Is Not Binding On The Court And Further Briefing And Proceedings Will Ensue

<p>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.84) by 7.14 percent.</p>


Guidance

TRML

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for <strong>McKesson Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded <strong>United States Cellular Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for <strong>Sarepta Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded <strong>Clearwater Analytics Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for <strong>Sinclair, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying MCK stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a></strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></strong></li>
</ul>


Pre-Market Outlook

Markets

Trading Ideas

CWAN

SBGI

SRPT

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

<p>Keefe, Bruyette &amp; Woods  analyst Paul Johnson   upgrades TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) from Underperform to Market Perform and lowers the price target from $8 to $7.5.</p>


TPVG

Keefe, Bruyette & Woods Upgrades TriplePoint Venture Gwth to Market Perform, Lowers Price Target to $7.5

Biotech

CARM

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

<p>Stephens &amp; Co.  analyst Jim Salera   reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.</p>


PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>We&rsquo;re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!</p>



<p>Moving stocks this morning are loads of earnings reports, clinical trial updates and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Ainos </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aimd-stock-quote/"><strong>AIMD</strong></a>) stock is rocketing more than 167% higher alongside heavy pre-market trading this morning.</li>



<li><strong>Mira Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/"><strong>MIRA</strong></a>) shares are soaring over 62% following an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318143679&amp;type=PDF&amp;symbol=MIRA&amp;cdn=5ac703f906d545e227a6921d3ddc5329&amp;companyName=MIRA+Pharmaceuticals+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-07">update on its clinical trials</a>.</li>



<li><strong>ReAlpha Tech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aire-stock-quote/"><strong>AIRE</strong></a>) stock is surging 52% with strong early morning trading today.</li>



<li><strong>CERo Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/"><strong>CERO</strong></a>) shares are swelling more than 32% as it continues to rally on <a href="https://www.nasdaq.com/press-release/cero-therapeutics-inc.-announces-publication-of-preclinical-research-supporting-the">preclinical trial data</a>.</li>



<li><strong>Gulf Island Fabrication</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gifi-stock-quote/"><strong>GIFI</strong></a>) stock is gaining over 23% alongside its <a href="https://www.nasdaq.com/press-release/gulf-island-reports-fourth-quarter-and-full-year-2023-results-2024-03-07">latest earnings report</a>.</li>



<li><strong>Quoin Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/"><strong>QNRX</strong></a>) shares are increasing more than 23% after releasing its <a href="https://www.nasdaq.com/press-release/quoin-pharmaceuticals-announces-fourth-quarter-and-2023-financial-results-and">Q4 earnings report</a>.</li>



<li><strong>DHC Acquisition</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhca-stock-quote/"><strong>DHCA</strong></a>) stock is rising over 23% on Friday morning.</li>



<li><strong>Auddia </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/auud-stock-quote/"><strong>AUUD</strong></a>) shares are climbing more than 23% this morning.</li>



<li><strong>Porch </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/prch-stock-quote/"><strong>PRCH</strong></a>) stock is jumping close to 21% with its <a href="https://www.nasdaq.com/press-release/porch-group-reports-fourth-quarter-2023-results-2024-03-07">most recent earnings report</a>.</li>



<li><strong>Grifols </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/grfs-stock-quote/"><strong>GRFS</strong></a>) shares are up over 16% after regaining lost ground from <a href="https://www.marketwatch.com/story/grifols-shares-rebound-after-kpmg-greenlights-accounts-in-wake-of-short-sellers-report-c5b7f357">a short report</a>.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li><strong>Affimed </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a>) stock is crashing more than 82% ahead of a <a href="https://www.nasdaq.com/press-release/affimed-announces-1-for-10-reverse-stock-split-2024-03-06">reverse stock split today</a>.</li>



<li><strong>AerSale </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/asle-stock-quote/"><strong>ASLE</strong></a>) shares are diving 20% after releasing its <a href="https://www.nasdaq.com/press-release/aersale-reports-fourth-quarter-and-full-year-2023-results-2024-03-07">Q4 earnings results</a>.</li>



<li><strong>BigBear.ai</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/bbai-stock-quote/"><strong>BBAI</strong></a>) stock is tumbling over 17% on a <a href="https://seekingalpha.com/news/4077463-bigbearai-stock-slides-22-after-hours-on-wider-quarterly-loss-revenue-miss">wider loss than expected</a>.</li>



<li><strong>Mustang Bio </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/"><strong>MBIO</strong></a>) shares are taking a more than 16% beating after jumping yesterday on <a href="https://www.nasdaq.com/press-release/mustang-bio-announces-publication-in-nature-medicine-of-data-from-phase-1-trial">clinical trial data</a>.</li>



<li><strong>Brera </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/"><strong>BREA</strong></a>) stock is sliding over 16% after rallying yesterday <a href="https://investorplace.com/2024/03/why-is-brera-brea-stock-up-128-today/">on investment news</a>.</li>



<li><strong>Lucas GC</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lgcl-stock-quote/"><strong>LGCL</strong></a></span>) shares are decreasing more than 15% after <a href="https://www.nasdaq.com/press-release/lucas-gc-limited-announces-closing-of-initial-public-offering-2024-03-07">closing a public offering</a>.</li>



<li><strong>Avinger</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgr-stock-quote/"><strong>AVGR</strong></a>) stock is dropping over 13% after rallying yesterday <a href="https://www.nasdaq.com/press-release/avinger-announces-strategic-partnership-and-up-to-%2415-million-equity-funding">on a strategic partnership</a>.</li>



<li><strong>Grom Social Enterprises</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/grom-stock-quote/"><strong>GROM</strong></a>) shares are falling more than 13% <a href="https://investorplace.com/2024/03/why-is-grom-social-grom-stock-up-40-today/">after jumping yesterday</a>.</li>



<li><strong>Kidpik </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pik-stock-quote/"><strong>PIK</strong></a>) stock is declining over 13% <a href="https://www.marketwatch.com/story/kidpik-shares-up-88-after-reverse-split-8ecddc3b">following a reverse split</a>.</li>



<li><strong>Ucommune International</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/"><strong>UK</strong></a>) shares close out our pre-market stock movers down more than 13%.</li>
</ol><p><em>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-march-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Grom Social Enterprises Inc (GROM) has fallen Monday morning, with the stock losing -1.87% in pre-market trading to 1.05. GROM's short-term technical score of 2 indicates that the stock has traded less bullishly over the last month than 98% of stocks on the market. In the Internet Content and Information industry, which ra

Grom Social Enterprises Inc (GROM) Down 1.87% in Premarket Trading

The 17 rating InvestorsObserver gives to Grom Social Enterprises Inc (GROM)  stock puts it near the bottom of the Communication Services sector.In addition to scoring higher than 9 percent of stocks in the Communication Services sector, GROMâ€&#x2122;s 17 overall rating means the stock scores better than 17 of all stocks. GROM has

Can Grom Social Enterprises Inc (GROM) Stock Rise to the Top of Communication Services Sector Thursday?

Grom Social Enterprises Inc (GROM) stock is lower by 14.95% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator. Grom Social Enterprises Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GROM!See Full GROM ReportWhat is Stock Sentim

What is the Market's View on Grom Social Enterprises Inc (GROM) Stock's Price and Volume Trends Friday?

CPOP, LEE among major communication services gainers; DRCT, CDLX among losers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Grom Social Enterprises</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/grom-stock-quote/"><strong>GROM</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Grom Social Enterprises reported earnings per share of -$1.80.</li><li>The company reported revenue of $914,642.</li><li>This was 44.90% worse than the analyst estimate for revenue of $1.66 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/grom-stock-earnings-grom-social-enterprises-for-q4-of-2023/">GROM Stock Earnings: Grom Social Enterprises Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GROM Stock Earnings: Grom Social Enterprises Misses Revenue for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Grom Social Enterprises</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/grom-stock-quote/"><strong>GROM</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Grom Social Enterprises reported earnings per share of -$1.47.</li><li>The company reported revenue of $874,232.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/grom-stock-earnings-grom-social-enterprises-for-q1-of-2024/">GROM Stock Earnings: Grom Social Enterprises Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GROM Stock Earnings: Grom Social Enterprises Reported Results for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>I&rsquo;m 100% on board when it comes to <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. If you choose correctly, I think they are a fine way to diversify your portfolio and gain exposure to some companies that are on the verge of some dynamic things that can bring you profits. But you have to choose the right stocks &mdash; and F-rated penny stocks are the ones you should be avoiding at all costs.</p>



<p>Penny stocks are those that sell for $5 or less per share, but there are plenty of penny stocks out there that are priced much less. When you&rsquo;re looking for penny stocks, it&rsquo;s important to recognize which ones are the up-and-comers and which ones are on their way down.</p>



<p>The latter on the list are the ones that you need to be very careful about. Bottom-feeding on an F-rated penny stock is a sure path to failure and losses. And it can happen fast &mdash; penny stocks can be very volatile because most of them have a small market cap and their trading volumes are often small &mdash; so it doesn&rsquo;t take a lot to move the stock price up or down.</p>



<p>Today we&rsquo;ll use the Portfolio Grader to identify F-rated penny stocks that you should be avoiding. By evaluating metrics such as momentum, earnings performance and revenue growth (or lack thereof), the Portfolio Grader gives you an objective look at all the stocks in the market &mdash; and can help steer you clear from trouble.</p>



<h2>Bruush Oral Care (BRSH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/ecommerce1600e-min-300x169.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Bruush Oral Care</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/brsh-stock-quote/"><strong>BRSH</strong></a>) is in the business of teeth. The company operates an e-commerce platform that sells sonic-powered electric toothbrushes and brush head refills.</p>



<p>The company offers a subscription program that, if successful, would provide Bruush with a consistent revenue stream. But the business model hasn&rsquo;t proven to be effective.</p>



<p>That&rsquo;s why the company performed a 1-for-25 reverse stock split in August in an attempt to maintain Nasdaq compliance, and that was a short-term solution at best, because the stock price is again far below the $1 threshold and Bruush is <a href="https://feeds.issuerdirect.com/news-release.html?newsid=5212830209014282">operating again under threat of a delisting</a>.</p>



<p>Late last year, Bruush and <strong>Arrive Technology</strong>, an Indiana company that offers a smart Mailbox-as-a-Service (Maas) platform that uses artificial intelligence to help deliver packages through drones and robot technology. The <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8931471892612331">merger</a>, which is expected to close this year, would see the combined company trade under the ticker symbol ARRV.</p>



<p>The expected merger helped push Bruush&rsquo;s stock price from 4 cents to 15 cents, but the stock is still an incredibly weak play. If gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Ascent Solar Technologies (ASTI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/solar-car-300x169.jpg" alt="Concept art of solar panels charging a vehicle."><div>Source: Shutterstock</div></div><p><strong>Ascent Solar Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/asti-stock-quote/"><strong>ASTI</strong></a>) is a Colorado company that makes photovoltaic panels on thin, film-like layers that can be used on solar panels, for drones and unmanned aircraft, and in space and defense applications.</p>



<p>The company recently touted a <a href="https://finance.yahoo.com/news/ascent-solar-technologies-receives-firm-125500740.html">new contract</a> it signed with an unnamed customer who plans to use Ascent&rsquo;s thin photovoltaic panels to power low Earth-orbit satellites.</p>



<p>But like Bruush, the company is also struggling to maintain its Nasdaq compliance. It completed a <a href="https://investor.ascentsolar.com/news/news-details/2023/Ascent-Solar-Technologies-Inc.-Announces-Reverse-Stock-Split/default.aspx">1-for-200 reverse stock split</a> in September, but the stock is already back below $1.</p>



<p>And the financials are painful to see. <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001350102/70643edd-d719-44de-9ec3-06a1f580d6aa.pdf">Revenue</a> in the first quarter was $5,600, down from $124,255 a year ago. The company posted a loss of $2.53 million in the quarter, which was better than the $6 million loss it recorded in the first quarter of 2023.</p>



<p>ASTI stock is down 83% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Ault Alliance (AULT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/stocks-to-buy-greedy1600-300x169.png" alt="man's hand holding wads of cash. stocks to buy. russell 2000 stocks to buy"><div>Source: Vova Shevchuk / Shutterstock.com</div></div><p><strong>Ault Alliance</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/ault-stock-quote/"><strong>AULT</strong></a>) is a holding company that seeks to buy undervalued businesses and invest in disruptive technologies. It has a number of affiliates, including Sentinum, which is a miner of <strong>Bitcoin</strong> (<a href="https://investorplace.com/cryptocurrency/btc-usd/"><strong>BTC-USD</strong></a>)</p>



<p>Ault doesn&rsquo;t even have a Nasdaq listing and trades on the <strong>NYSE American</strong>, which is the small cap equity market exchange. But like other names on this list, it&rsquo;s had some difficulties there maintaining compliance. Ault announced on May 2 that it&rsquo;s managed to regain compliance.</p>



<p>But it may be a short-term victory. The stock price is down to 33 cents per share, having lost 84% of its value this year, including 15% in the last week.</p>



<p>AULT stock gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Grom Social Enterprises (GROM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/socialmedia1600c-300x169.jpg" alt="hands holding smartphone with social media icons floating above it. brick wall background."><div>Source: Shutterstock</div></div><p><strong>Grom Social Enterprises</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/grom-stock-quote/"><strong>GROM</strong></a>) is a Florida company that runs a social media platform that&rsquo;s targeted to kids. Most social media platforms require users to be at least 13, but Grom is for kids younger than that.</p>



<p>The platform lets kids share content and chat in an online environment that is monitored by Grom employees.</p>



<p>However, the business is shrinking fast. <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&amp;ref=318336323&amp;type=HTML&amp;symbol=GROM&amp;cdn=e70fcb07a2d4eb401b3649bdbecbe45a&amp;companyName=Grom+Social+Enterprises+Inc.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-05-20">Revenues</a> in the first quarter were only $874,000 down from $1.19 million. The company posted a net loss of $4.1 million, up from a loss of $2.3 million in the first quarter of 2023. Grom acknowledged seeing steep drops in animation revenue, sales and a loss of multiyear contract renewals.</p>



<p>Grom now only has cash and cash equivalents of $450,000, and debts of $100.9 million. In a recent filing, the company acknowledged that it will need to raise additional funding to continue.</p>



<p>GROM stock is down 56% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/spce-1600-300x169.jpg" alt="spce stock"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>Virgin Galactic</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/"><strong>SPCE</strong></a>) is probably one of the most well-known F-rated penny stocks on this list. The company a few short years ago was in a race with SpaceX and Blue Orgin to see which would be the first private company to successfully launch a civilian into space and open the door toward space tourism.</p>



<p>Virgin Galactic won that race, as founder Richard Branson made his first suborbital spaceflight just nine days before Jeff Bezos went up in a Blue Origin ship. But that&rsquo;s pretty much been the highlight for Virgin Galactic. </p>



<p>The company&rsquo;s encountered steep losses, burning through more than $1 billion in the last two years.</p>



<p>And while there&rsquo;s renewed interest in SPCE stock today in advance of the company&rsquo;s planned Unity spacecraft launch on June 8, space tourism is still a rich person&rsquo;s game with no profits to be had for investors.</p>



<p>SPCE stock is down 61% in 2024 and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div><p><strong>MicroVision</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/"><strong>MVIS</strong></a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function. The sensors are also used in industrial, smart infrastructure and robotics.</p>



<p>While there are useful applications for MicroVision&rsquo;s products, the company hasn&rsquo;t been able to turn that into a profit. </p>



<p>Revenue for the first quarter was an improvement, coming in at $956,000 versus $782,000 a year ago. But the company&rsquo;s losses were massive, coming in at $26.3 million and 13 cents per share versus $19 million and 11 cents per share a year ago.</p>



<p>And there doesn&rsquo;t appear to be a plan to turn things around, other than &ldquo;work harder.&rdquo;</p>



<p>&ldquo;As we navigate current headwinds in the automotive industry and lidar sector with a healthy balance of optimism and realism, we are aggressively pursuing near-term revenue opportunities in industrial markets and with partnership opportunities, as well as continuing our ethos of fiscal discipline,&rdquo; CEO Sumit Sharma said. &ldquo;I remain committed to steering MicroVision and firmly establishing it as a leading automotive OEM supplier of lidar hardware and software solutions.&rdquo;</p>



<p>I would rather see a bold plan for turning this ship around. But that&rsquo;s why MicroVision is an F-rated penny stock in the Portfolio Grader. The stock price is down 58% this year.</p>



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>Mullen Automotive</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/"><strong>MULN</strong></a>) is a struggling electric vehicle stock that&rsquo;s made huge moves in the last year to try to maintain its Nasdaq listing.</p>



<p>Remember, this is the EV company that did three separate reverse stock splits last year, including a 1-for-100 split in December.</p>



<p>To its credit, Mullen is trying to do something different now. It&rsquo;s shifting its business model to produce commercial EVs, and it&rsquo;s completed the first phase of its&nbsp;<a href="https://investorplace.com/2024/04/muln-stock-alert-mullen-hits-new-battery-pack-milestone/">battery line integration</a>&nbsp;at its California plant in hopes of commercializing EV battery packs.</p>



<p>It&rsquo;s working on expanding its distribution network into <a href="https://finance.yahoo.com/news/mullen-announces-european-distributor-gama-130000336.html">Eastern Europe</a> and it signed a new deal to supply 40 commercial vehicles to a company in <a href="https://finance.yahoo.com/news/mullen-automotive-secures-major-european-183010622.html">Switzerland</a>.</p>



<p>Is this enough to turn the tide on MULN stock? Its finally starting to see revenue, <a href="https://news.mullenusa.com/mullen-reports-q2-2024-fiscal-quarter-results">bringing in $33,000 in the second quarter of fiscal 2024</a>. But the losses are staggering, at $177.3 million for the quarter.</p>



<p>Mullen has $22.3 million in cash and cash equivalents, down from $155 million a year ago. So at this rate of spending, money is going to be an immediate concern. While it&rsquo;s possible that Mullen can eventually become a stable company, it&rsquo;s nowhere close now.</p>



<p>MULN stock is down 73% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Louis&nbsp;Navellier did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em> <em>The InvestorPlace Research Staff member primarily responsible for this article had a long position in BTC-USD. The staff member did not hold (either directly or indirectly) any other positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/05/7-f-rated-penny-stocks-not-worth-shaking-a-stick-at/">7 F-Rated Penny Stocks Not Worth Shaking a Stick At</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 F-Rated Penny Stocks Not Worth Shaking a Stick At

AFMD

AIMD

AIRE

ASLE

ASTI

AULT

AUUD

AVGR

BBAI

BREA

BRSH

CDLX

CERO

CPOP

DGLY

DHCA

DRCT

GIFI

GRFS

GROM

LGCL

MBIO

MIRA

MULN

MVIS

MYPS

PRCH

QNRX

SPCE

WIMI

Contracts

Press Releases

Top Draw Animation Secures New Assignments – Including Largest Single Contract Ever – as Grom Subsidiary Earns Over $2.9MM to Bring Animated Series' to Life

Redesigned Grom Social App, Debuting This Summer, to Feature Custom Avatars Offering Kids Tips on Responsible Social Media Behavior Utilizing Grom Educational's Digital Citizenship License (DCL) Course

Comments

Grom Social Enterprises

Grom Social Enterprises (GROM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO